Drug Profile

PAS 003

Alternative Names: Alpha-5 - Pasithea Therapeutics; PAS-003

Latest Information Update: 07 Aug 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Alpha-5 Integrin
Developer Pasithea Therapeutics
Class Monoclonal antibodies; Neuroprotectants
Mechanism of Action Integrin alpha 5 beta 1 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Amyotrophic lateral sclerosis; Neurological disorders

Most Recent Events

01 Aug 2023 Pharmacodynamics data from a preclinical studies in Amyotrophic lateral sclerosis released by Pasithea Therapeutics
22 Jun 2022 Preclinical trials in Neurological disorders in USA (Parenteral)
22 Jun 2022 Alpha-5 Integrin has been acquired and merged into Pasithea Therapeutics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com